患者女性,49岁,汉族。

主诉：结肠癌姑息切除术后3周。

现病史：2005年10月因“转移性右下腹疼痛,持续性,伴恶心、呕吐”在我院行“右半结肠切除术”,术中见结肠系膜和壁腹膜有米粒样播散结节,肝脾未发现结节,盆腔腹膜及右侧卵巢可扪及播散结节。术后3周至我科行姑息化疗。

既往史、个人史及家族史：均无特殊。

体格检查：身高158cm,体重52kg,体表面积1.51m²,KPS评分90分。发育正常,全身浅表淋巴结未触及肿大；心肺无特殊体征。腹部可见术后瘢痕,肝脾肋下未触及。

辅助检查：病理诊断：中分化管状腺癌,浸润全层,浸及肠旁脂肪组织,腹膜种植病灶见癌浸润。淋巴结45/45转移；化疗前CT检查：全身未见明显转移灶。

诊断：进展期结肠癌（Duke’s D期）R₂。

及

：于2005年11月至2006年4月予mFOLFOX6（草酸铂+5-FU/CF）双周方案化疗,2006年8月再次出现腹痛,复查腹部CT考虑升结肠癌卵巢转移。2006年10月予Xliri（伊立替康+希罗达）三周方案化疗。三疗程后评价疗效为进展,腹痛症状加重,于2006年12月开始予以5-FU300mg/天入百特泵持续滴注,2月后复查CT提示病灶轻度缩小,疼痛明显缓解,评价疗效为稳定（SD）；持续予5-FU 300mg/天滴注直至2007年7月,复查CT示病灶较前增大,持续滴注时间为6个月。期间患者耐受性良好,无恶心、呕吐,滴注过程中患者无需止呕处理；百特泵为便携式,滴注过程中,患者无需住院,每5天来院换泵并行深静脉留置管护理。肿瘤进展后予其他含5-FU/CF方案及局部姑息性放疗,肿瘤控制不理想,8个月后死于肿瘤进展。

1.Jassem J,Pienkowski T,Pluzanska A,et al.Doxorubicin and paclitaxel versus fluorouracil,doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer：long-term analysis of the previously published trial\[J\].Onkologie,2009,32（8-9）：468-472.

2.Chang AY,Lopes G,Hsin KW,et al.PhaseⅡtrial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma：a cancer therapeutics research group study\[J\].Clin Colorectal Cancer,2007,6（9）：646-651.

3.Bae WK,Hwang JE,Shim HJ,et al.PhaseⅡstudy of docetaxel,cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer\[J\].Cancer Chemother Pharmacol,2010,65（3）：589-595.

4.Longley DB,Harkin DP,Johnston PG,et al.5-fluorouracil：Mechanisms of action and clinical strategies\[J\].Nat Rev Cancer,2003,3（5）：330-338.

5.Hoff PM,Ansari R,Batist G,et al.Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605patients with metastatic colorectal cancer：results of a randomized phaseⅢstudy\[J\].J Clin Oncol,2001,19（8）：2282-2292.

6.Folkman J.Anti-angiogenesis：new concept for therapy of solid tumors\[J \].Ann Surg,1972,175（3）：409-416.

7.Hanahan D,Bergers G,Bergsland E.Less is more regularly：metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice\[J\].J Clin Invest,2000,105（8）：1045-1047.

8.Colleoni M,Rocca A,Sandri MT,et al.Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer：antitumor activity and correlation with vascular endothelial growth factor levels\[J\].Ann Oncol,2002, 13（1）：73-80.

9.Glode LM,Barqawi A,Crighton F,et al.Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.Cancer,2003,98（8）：1643-1648.

10.Ooyama A,Oka T,Zhao H,et al.Anti-angiogenic effect of 5-Fluorouracilbased drugs against human colon cancer xenografts\[J\].Cancer Lett, 2008,267（1）：26-36.

11.Van Cutsem E,Geboes K.The multidisciplinary management of gastrointestinal cancer.The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer\[J\].Best Pract Res Clin Gastroenterol,2007,21（6）：1089-1108.

12.Goldberg RM.Advances in the treatment of metastatic colorectal cancer\ [J\].Oncologist,2005,10（Suppl）：340-348.

13.Hicklin DJ,Ellis LM.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis\[J\].J Clin Oncol,2005,23（5）：1011-1027.

14.Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer\[J\].N Engl J Med,2004,350（23）：2335-2342.

15.Hurwitz HI,Fehrenbacher L,Hainsworth JD,et al.Bevacizumab in combination with fluorouracil and leucovorin：an active regimen for first-line metastatic colorectal cancer\[J\].J Clin Oncol,2005,23（15）：3502-3508.

16.Fuchs CS,Marshall J,Mitchell E,et al.Randomized,controlled trial of irinotecan plus infusional,bolus,or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer：results from the BICC-C Study\[J \].J Clin Oncol,2007,25（30）：4779-4786.

17.Saltz LB,Clarke S,Díaz-Rubio E,et al.Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer：a randomized phaseⅢstudy\[J\].J Clin Oncol,2008,26（12）：2013-2019.

18.Sobrero AF,Maurel J,Fehrenbacher L,et al.EPIC：phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer\[J\].J Clin Oncol,2008,26（14）：2311-2319.

19.Van Cutsem E,Nowacki M,Lang I,et al.Randomized phaseⅢstudy of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer（mCRC）：The CRYSTAL trial\[J\].J Clin Oncol,2007,25（suppl18）：4000.

20.Lièvre A,Bachet JB,Le Corre D,et al.KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer\[J\].Cancer Res, 2006,66（8）：3992-3995.

21.Van Cutsem E,Peeters M,Siena S,et al.Open-label phaseⅢtrial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer \[J\].J Clin Oncol,2007,25：1658-1664.

22.Kerbel RS,Kamen BA.The anti-angiogenic basis of metronomic chemotherapy\[J\].Nat Rev Cancer,2004,4（6）：423-436.

23.Browder T,Butterfield CE,Krling BM,et al.Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer\[J\].Cancer Res,2000,60（7）：1878-1886.

24.Bertolini F,Paul S,Mancuso P,et al.Maximum tolerable dose and lowdose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells\[J\].Cancer Res, 2003,63（15）：4342-4346.

25.Ghiringhelli F,Menard C,Puig PE,et al.Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+regulatory T cells and restores T and NK effector functions in end stage cancer patients\[J\].Cancer Immunol Immunother,2007,56（5）：641-648.